JPWO2021021717A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021021717A5 JPWO2021021717A5 JP2022505447A JP2022505447A JPWO2021021717A5 JP WO2021021717 A5 JPWO2021021717 A5 JP WO2021021717A5 JP 2022505447 A JP2022505447 A JP 2022505447A JP 2022505447 A JP2022505447 A JP 2022505447A JP WO2021021717 A5 JPWO2021021717 A5 JP WO2021021717A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- adenosine derivative
- acceptable salt
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962879414P | 2019-07-27 | 2019-07-27 | |
| US62/879,414 | 2019-07-27 | ||
| PCT/US2020/043713 WO2021021717A1 (en) | 2019-07-27 | 2020-07-27 | Adenosine derivative and pharmaceutical composition comprising the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022541667A JP2022541667A (ja) | 2022-09-26 |
| JPWO2021021717A5 true JPWO2021021717A5 (es) | 2023-08-07 |
Family
ID=74229552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022505447A Pending JP2022541667A (ja) | 2019-07-27 | 2020-07-27 | アデノシン誘導体及びそれを含む薬学的組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20220288098A1 (es) |
| EP (1) | EP4003369A4 (es) |
| JP (1) | JP2022541667A (es) |
| KR (1) | KR20220068987A (es) |
| CN (1) | CN114502175A (es) |
| AU (1) | AU2020320876A1 (es) |
| BR (1) | BR112022000965A2 (es) |
| CA (1) | CA3146679A1 (es) |
| IL (1) | IL289925A (es) |
| MX (1) | MX2022000563A (es) |
| TW (1) | TW202118496A (es) |
| WO (1) | WO2021021717A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117982682A (zh) | 2017-07-11 | 2024-05-07 | 吉利德科学公司 | 用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物 |
| CN114929236B (zh) * | 2019-09-11 | 2024-06-07 | 斯克里普斯研究所 | 抗病毒前药及其制剂 |
| KR20220132608A (ko) | 2020-01-27 | 2022-09-30 | 길리애드 사이언시즈, 인코포레이티드 | SARS CoV-2 감염증을 치료하기 위한 방법 |
| KR20220153619A (ko) | 2020-03-12 | 2022-11-18 | 길리애드 사이언시즈, 인코포레이티드 | 1'-시아노 뉴클레오사이드의 제조 방법 |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| US11701372B2 (en) | 2020-04-06 | 2023-07-18 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carba-nucleoside analogs |
| TW202203941A (zh) | 2020-05-29 | 2022-02-01 | 美商基利科學股份有限公司 | 瑞德西韋之治療方法 |
| MX2022016405A (es) | 2020-06-24 | 2023-01-30 | Gilead Sciences Inc | Análogos de nucleósido de 1¿-ciano y usos de estos. |
| CR20230104A (es) | 2020-08-27 | 2023-04-28 | Gilead Sciences Inc | Compuestos y métodos para el tratamiento de infecciones virales |
| MX2023008004A (es) | 2021-01-25 | 2023-07-13 | Brii Biosciences Inc | Derivado de adenosina y composicion farmaceutica que lo comprende. |
| CA3204255A1 (en) * | 2021-01-25 | 2022-07-28 | Lianhong Xu | Combination therapy for hiv with adenosine derivative and capsid inhibitors |
| IL307967A (en) * | 2021-04-28 | 2023-12-01 | Astrocyte Pharmaceuticals Inc | Purine nucleosides, their intermediates and methods for their preparation |
| IL315102A (en) | 2022-03-02 | 2024-10-01 | Gilead Sciences Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| WO2023196832A2 (en) * | 2022-04-06 | 2023-10-12 | Brii Biosciences, Inc. | Pharmaceutical composition and method for treatment of human immunodeficiency virus infections |
| WO2024163262A2 (en) * | 2023-01-30 | 2024-08-08 | Merck Sharp & Dohme Llc | Prodrugs of 4'-substituted nucleoside reverse transcriptase inhibitors |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004271972B2 (en) * | 2003-09-05 | 2010-06-03 | Anadys Pharmaceuticals, Inc. | TLR7 ligands for the treatment of hepatitis C |
| CA2502109C (en) * | 2004-03-24 | 2010-02-23 | Yamasa Corporation | 4'-c-substituted-2-haloadenosine derivative |
| JP2009504677A (ja) * | 2005-08-12 | 2009-02-05 | メルク・エンド・カムパニー・インコーポレーテツド | 新規２’−ｃ−メチル及び４’−ｃ−メチルヌクレオシド誘導体 |
| WO2017053216A2 (en) * | 2015-09-23 | 2017-03-30 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof |
| EP3844164A1 (en) * | 2018-08-30 | 2021-07-07 | GlaxoSmithKline Intellectual Property (No.2) Limited | Compounds useful in hiv therapy |
-
2020
- 2020-07-27 WO PCT/US2020/043713 patent/WO2021021717A1/en unknown
- 2020-07-27 JP JP2022505447A patent/JP2022541667A/ja active Pending
- 2020-07-27 AU AU2020320876A patent/AU2020320876A1/en active Pending
- 2020-07-27 CN CN202080066036.3A patent/CN114502175A/zh active Pending
- 2020-07-27 US US17/630,403 patent/US20220288098A1/en active Pending
- 2020-07-27 EP EP20848596.1A patent/EP4003369A4/en active Pending
- 2020-07-27 CA CA3146679A patent/CA3146679A1/en active Pending
- 2020-07-27 KR KR1020227006549A patent/KR20220068987A/ko unknown
- 2020-07-27 BR BR112022000965A patent/BR112022000965A2/pt unknown
- 2020-07-27 TW TW109125342A patent/TW202118496A/zh unknown
- 2020-07-27 MX MX2022000563A patent/MX2022000563A/es unknown
-
2022
- 2022-01-17 IL IL289925A patent/IL289925A/en unknown
-
2023
- 2023-02-28 US US18/176,204 patent/US20230226093A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2021021717A5 (es) | ||
| RU2403258C2 (ru) | Тиазолилдигидроиндазолы | |
| ES2622471T3 (es) | Compuestos y procedimientos para la administración de análogos de prostaciclina | |
| ES2219895T3 (es) | Formulacion autoemulsionante para compuestos lipofilos. | |
| JP5005847B2 (ja) | 親油性化合物用の自己乳化性処方 | |
| JP2991733B2 (ja) | 乾癬疾患を抑制するための薬剤及びその製法 | |
| JP6445591B2 (ja) | シロリムス及びその誘導体の複合体、それらの調製方法ならびにそれらを含有する医薬組成物 | |
| RU2662819C2 (ru) | Твердая дисперсия с улучшенной растворимостью, содержащая производное тетразола в качестве активного ингредиента | |
| ES2384333T3 (es) | Composiciones farmacéuticas que tienen perfiles de disolución mejorados para fármacos poco solubles | |
| CN113747896A (zh) | 来那度胺和其他免疫调节剂的连续递送 | |
| AU725965B2 (en) | Method of enhancing bioavailability of fexofenadine and its derivatives | |
| EP2231148A2 (en) | Pharmaceutical composition for the treatment and prevention of cardiac disease | |
| KR20140016926A (ko) | 활성제로서 페닐아미노피리미딘 유도체를 포함하는 제제 | |
| RU2022104985A (ru) | Аденозиновое производное и фармацевтическая композиция, содержащая его | |
| JP5613396B2 (ja) | 腸管吸収性を改善する医薬組成物 | |
| JP5936609B2 (ja) | キナーゼインヒビターの経口製剤 | |
| JP4808246B2 (ja) | 医薬組成物 | |
| RU2018142381A (ru) | Фармацевтический препарат | |
| JPH10503178A (ja) | Ｈｉｖ感染のための組合わせ療法 | |
| KR101118199B1 (ko) | 타크롤리무스를 가용화하기 위한 고분자 미셀 조성물 | |
| AU2018294561A1 (en) | New oral formulations of belinostat | |
| PT95007A (pt) | Processo para a preparacao de agentes terapeuticos contendo derivados de xantina e para a preparacao desses derivados | |
| JP2008208122A (ja) | 肥満の予防及び／又は治療薬 | |
| TW200423972A (en) | Tablet having improved solubility | |
| CA3188796A1 (en) | Thromboxane receptor antagonist formulations |